MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 65
- Registration Number
- NCT03244800
- Locations
- 🇩🇪
Research Site, Neuss, Germany
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 37
- Registration Number
- NCT03235375
- Locations
- 🇳🇿
Research Site, Christchurch, New Zealand
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 35
- Registration Number
- NCT03162224
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT03158038
- Locations
- 🇺🇸
Research Site, Portland, Oregon, United States
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 200
- Registration Number
- NCT03143101
- Locations
- 🇺🇸
Research Site, West Jordan, Utah, United States
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 67
- Registration Number
- NCT03106428
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 88
- Registration Number
- NCT03096795
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 39
- Registration Number
- NCT03089645
- Locations
- 🇦🇺
Research Site, Randwick, Australia
Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT03028909
Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03004638
- Locations
- 🇺🇸
Research Site, Cincinnati, Ohio, United States
© Copyright 2024. All Rights Reserved by MedPath